BIO-RAD LABORATORIES, INC.: management transactions · United States · SEC (Form 4)

About BIO-RAD LABORATORIES, INC.

BIO-RAD LABORATORIES, INC. is a leading provider of life science research tools and clinical diagnostics products. The company is listed on the U.S. market, specifically the NYSE (tickers BIO and BIO.B), and is headquartered in Hercules, California, United States. Bio-Rad was founded in 1952 in Berkeley by David and Alice Schwartz, initially building specialty chemical products before evolving into a global platform for research reagents, instruments, and clinical diagnostic systems. ([bio-rad.com](https://www.bio-rad.com/fr-fr/corporate/about-bio-rad?ID=1003&utm_source=openai)) Today, Bio-Rad operates through two core business segments: Life Science and Clinical Diagnostics. The Life Science division supplies instruments, systems, consumables, and reagents used to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. These products serve academic research, biopharma, bioprocessing, quality control, food safety, and scientific education markets. The Clinical Diagnostics segment offers a broad range of products for clinical laboratories, with exposure to quality controls, blood typing, diabetes testing, and infectious disease applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12208/000001220825000007/bio-20241231.htm)) From a competitive standpoint, Bio-Rad occupies a strong niche in specialized, high-value laboratory technologies. Its customer base is broad and diversified, including universities, research institutions, hospitals, biopharmaceutical companies, and clinical and applied laboratories. In 2024, the company reported that roughly 41% of consolidated sales came from the United States and about 59% from international markets, with Europe its largest non-U.S. region. It also maintains direct distribution channels in more than 36 countries outside the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/12208/000001220825000007/bio-20241231.htm)) Bio-Rad’s product portfolio is anchored by its Droplet Digital PCR platform, molecular biology reagents, lab instrumentation, and a large diagnostic menu. Recent strategic moves have reinforced this positioning. In 2025, Bio-Rad completed the acquisition and integration of Stilla Technologies, strengthening its digital PCR leadership. The company also expanded access to more than 1,200 clinical diagnostics products globally through new regulatory registrations in over 60 countries and advanced oncology-focused diagnostic partnerships with Gencurix and Biodesix. ([investors.bio-rad.com](https://investors.bio-rad.com/press-releases/news-details/2026/Bio-Rad-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx)) Recent operating trends have been mixed. Full-year 2025 revenue was essentially flat on a currency-neutral basis, with Life Science pressured by weak academic research and biotech funding, while Clinical Diagnostics posted more resilient growth. In the first quarter of 2026, reported sales increased 1.1% year over year, but management lowered full-year 2026 expectations, citing a still-challenging environment. For investors, Bio-Rad remains a high-quality healthcare tools and diagnostics company, but one that is exposed to research funding cycles, foreign exchange volatility, regulatory execution, and the pace of recovery in biotech end markets. ([investors.bio-rad.com](https://investors.bio-rad.com/press-releases/news-details/2026/Bio-Rad-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx))